CTCA at Western Regional Medical Center launches Phase II of PembroPlus clinical trial

(Cancer Treatment Centers of America) This innovative 'PembroPlus' clinical trial combines an immunotherapy drug (pembrolizumab) with already FDA-approved chemotherapy drugs (gemcitabine, docetaxel, nab-paclitaxel, vinorelbine, irinotecan, and/or liposomal doxorubicin). The addition of pembrolizumab is aimed at activating the body's own immune system to improve the results that otherwise might be achieved from chemotherapy alone. This combination of chemotherapy drugs is investigational in this study.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news